XOMA Royalty (NASDAQ:XOMA) Stock Price Passes Above 200 Day Moving Average – Should You Sell?

XOMA Royalty Corporation (NASDAQ:XOMA) shares passed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $30.13 and traded as high as $30.50. XOMA Royalty shares last traded at $30.25, with a volume of 76,544 shares.

Wall Street Analysts Forecast Growth

XOMA has been the topic of several recent research reports. Stifel Nicolaus set a $50.00 price objective on shares of XOMA Royalty in a report on Friday, December 12th. TD Cowen upgraded shares of XOMA Royalty to a “hold” rating in a research note on Friday, February 13th. Zacks Research lowered shares of XOMA Royalty from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 10th. Leerink Partners reaffirmed an “outperform” rating on shares of XOMA Royalty in a report on Tuesday, February 24th. Finally, Benchmark reiterated a “buy” rating on shares of XOMA Royalty in a research note on Friday, December 12th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $61.60.

XOMA Royalty Trading Up 5.5%

The company has a debt-to-equity ratio of 1.15, a quick ratio of 3.37 and a current ratio of 3.37. The firm has a market cap of $394.31 million, a P/E ratio of 22.66 and a beta of 0.68. The firm has a 50 day simple moving average of $26.62 and a 200 day simple moving average of $30.11.

XOMA Royalty (NASDAQ:XOMA) last announced its quarterly earnings results on Wednesday, March 18th. The biotechnology company reported $0.12 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.16. XOMA Royalty had a return on equity of 10.32% and a net margin of 45.75%.The firm had revenue of $13.76 million for the quarter, compared to analysts’ expectations of $11.13 million. On average, equities research analysts predict that XOMA Royalty Corporation will post -1.41 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. raised its position in shares of XOMA Royalty by 3,436.4% in the third quarter. Russell Investments Group Ltd. now owns 778 shares of the biotechnology company’s stock worth $30,000 after buying an additional 756 shares in the last quarter. State of Alaska Department of Revenue purchased a new position in XOMA Royalty during the fourth quarter worth about $27,000. Tower Research Capital LLC TRC increased its stake in XOMA Royalty by 203.1% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,273 shares of the biotechnology company’s stock worth $57,000 after acquiring an additional 1,523 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of XOMA Royalty by 266.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 3,226 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,346 shares in the last quarter. Finally, JPMorgan Chase & Co. raised its holdings in shares of XOMA Royalty by 13.9% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,440 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 543 shares in the last quarter. 95.92% of the stock is owned by institutional investors.

About XOMA Royalty

XOMA Royalty (NASDAQ: XOMA) is a specialty healthcare royalty company that acquires and manages royalty interests in small-molecule and biologic drugs. The company’s business model centers on purchasing royalty streams on marketed or near-market pharmaceutical products, providing capital to developers in exchange for a share of future net sales. By focusing on late-stage assets with established clinical and commercial profiles, XOMA Royalty aims to generate predictable, long-term cash flows for its shareholders.

The company’s investment portfolio spans a range of therapeutic areas, including oncology, immunology and rare diseases.